ZEB1 and melanoma: Functional studies revealed that ZEB1 overexpression is sufficient to drive the emergence of resistance to BRAFi alone or in combination with MEKi, whereas ZEB1 inhibition sensitizes naive melanoma cells to BRAFi, prevents the emergence of resistance upon chronic exposure in vitro, and decreases the viability of resistant cells.